Cardiovascular disease has been the cause of more deaths annually than any other disease area for the last hundred years. While there have been multiple advances in our understanding of the underlying pathophysiology of cardiovascular disease and in developing important new therapeutics, drug discovery in this area is challenged by the need to balance robust efficacy with exquisite safety. For more than twenty-five years our research group has focused on discovering novel therapeutics to combat cardiovascular disease. This presentation will describe multiple short vignettes from our drug discovery efforts that highlight lessons learned which are applicable to current and future drug discovery efforts. Included will be the lessons learned from the discovery of two successful drugs discovered by our team, losartan, the first in class angiotensin II receptor antagonist, and apixaban, marketed as Eliquis®, a novel oral factor Xa inhibitor. Additionally, challenges and key learnings will be described from other clinical candidates discovered by our team, which were shown not to be viable as useful therapeutics when investigated in clinical trials.

<b>Award Address </b>(E. B. Hershberg Award for Important Discoveries in Medicinally Active Substances sponsored by Merck Research Laboratories). Adventures in cardiovascular drug discovery: New frontiers and lessons learned

249th National Meeting (2015)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.

Award Address (E. B. Hershberg Award for Important Discoveries in Medicinally Active Substances sponsored by Merck Research Laboratories). Adventures in cardiovascular drug discovery: New frontiers and lessons learned